Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1 study to assess safety and tolerability of a single subcutaneous dose of Dengusiil in healthy adults of 18 to 45 years of age. In this study, immune response to Dengusiil will also be assessed over a period of 6 months and vaccine viremia will also be assessed over a period of 12 days after administration of vaccine.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04035278
Study type Interventional
Source Serum Institute of India Pvt. Ltd.
Contact
Status Completed
Phase Phase 1
Start date December 17, 2019
Completion date June 11, 2021